78 related articles for article (PubMed ID: 17572515)
1. Using behavioral measurement to assess tumor progression and functional outcome after antiangiogenic treatment in mouse glioma models.
Yang H; Chopp M; Zhang X; Jiang F; Zhang Z; Kalkanis S; Schallert T
Behav Brain Res; 2007 Aug; 182(1):42-50. PubMed ID: 17572515
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
3. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
4. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
[TBL] [Abstract][Full Text] [Related]
7. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors.
Fenton BM; Paoni SF; Ding I
Radiother Oncol; 2004 Aug; 72(2):221-30. PubMed ID: 15297140
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with antiangiogenic treatment and photodynamic therapy for the nude mouse bearing U87 glioblastoma.
Jiang F; Zhang X; Kalkanis SN; Zhang Z; Yang H; Katakowski M; Hong X; Zheng X; Zhu Z; Chopp M
Photochem Photobiol; 2008; 84(1):128-37. PubMed ID: 18173712
[TBL] [Abstract][Full Text] [Related]
10. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
11. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
Roth P; Kissel M; Herrmann C; Eisele G; Leban J; Weller M; Schmidt F
Clin Cancer Res; 2009 Nov; 15(21):6609-18. PubMed ID: 19825946
[TBL] [Abstract][Full Text] [Related]
12. A novel model of intramedullary spinal cord tumors in rats: functional progression and histopathological characterization.
Caplan J; Pradilla G; Hdeib A; Tyler BM; Legnani FG; Bagley CA; Brem H; Jallo G
Neurosurgery; 2006 Jul; 59(1):193-200; discussion 193-200. PubMed ID: 16823316
[TBL] [Abstract][Full Text] [Related]
13. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
14. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antiglioma activity of radiotherapy and enzastaurin.
Tabatabai G; Frank B; Wick A; Lemke D; von Kürthy G; Obermüller U; Heckl S; Christ G; Weller M; Wick W
Ann Neurol; 2007 Feb; 61(2):153-61. PubMed ID: 17212356
[TBL] [Abstract][Full Text] [Related]
16. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
[TBL] [Abstract][Full Text] [Related]
17. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.
Bian XW; Yang SX; Chen JH; Ping YF; Zhou XD; Wang QL; Jiang XF; Gong W; Xiao HL; Du LL; Chen ZQ; Zhao W; Shi JQ; Wang JM
Neurosurgery; 2007 Sep; 61(3):570-8; discussion 578-9. PubMed ID: 17881971
[TBL] [Abstract][Full Text] [Related]
18. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
20. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
